Skip to content

ArriVent BioPharma, Inc. AVBP Short-Term Investments

Short-Term Investments at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$363M+18.2%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$221.17M-38.3%
Nuvation Bio logo
Nuvation BioNUVB
$408.34M-1.3%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$621M-22.9%
Erasca, Inc. logo
Erasca, Inc.ERAS
$196.53M-16.0%
Bicara Therapeutics logo
Bicara TherapeuticsBCAX
$216.29M

Other financials

Income statement

See full
Operating income-$46.1M+30.9%
Net income-$43.3M+32.7%
EPS (diluted)-$0.96+49.5%

Balance sheet

See full
Cash & equivalents$62.1M+24.5%
Total debt$419.0K+204%
Total equity$324.0M+60.0%
Total assets$349.3M+62.1%

Cash flow

See full
Operating cash flow-$41.9M+38.4%

Valuation

See full
Market cap$1.57B+62.1%
Enterprise value$1.51B+65.4%

Returns & leverage

See full
Return on equity-55.2%+8.0pp
Debt / equity0.0×
Current ratio14×-0.4×

Where this comes from

Reported directly by ArriVent BioPharma, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ShortTermInvestments.

The official record: ArriVent BioPharma, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about ArriVent BioPharma, Inc.'s short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is ArriVent BioPharma, Inc.'s short-term investments?
ArriVent BioPharma, Inc. (AVBP) reported short-term investments of $264.28M in Q1 2026.
How has ArriVent BioPharma, Inc.'s short-term investments changed year-over-year?
ArriVent BioPharma, Inc.'s short-term investments increased by 109.4% year-over-year, from $126.21M to $264.28M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.